Phase 3 Readout
KYNB: Phase 3 Topline: ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metasta
December 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 1, 2026
- Company
- KYNTRA BIO INC. (KYNB)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metasta
- Company
- KYNTRA BIO INC. (KYNB)
- Indication
- Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)